Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Diabet Med ; 26(7): 700-7, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19573119

ABSTRACT

AIMS: The Comprehensive ICF Core Set for diabetes mellitus (DM) is a specific application of the International Classification of Functioning, Disability and Health (ICF) of the World Health Organization for clinical and research purposes involving the disorder. It represents the typical spectrum of functional problems in patients with DM. The objective of the study was to validate the Comprehensive ICF Core Set for DM from the perspective of patients. The specific aims were to explore the aspects of function and health important to patients with DM using focus group methodology and to examine to what extent these aspects are represented by the Comprehensive ICF Core Set for DM. METHODS: A qualitative study using focus group methodology was conducted. Sampling of patients followed the maximum variation strategy. Sample size was determined by saturation. The focus group discussions were digitally recorded and transcribed verbatim. The meaning condensation procedure was used for data analysis. The resulting meaningful concepts were linked to ICF categories according to established linking rules. RESULTS: Forty patients participated in eight focus groups. Seventy-five of the 85 ICF categories contained in the Comprehensive ICF Core Set for DM were identified by the patients. Forty-seven additional categories that are not covered by the Comprehensive ICF Core Set for DM were identified. CONCLUSIONS: The Comprehensive ICF Core Set for DM could be largely confirmed by the focus groups. Categories currently not covered by the Comprehensive ICF Core Set for DM should be investigated further.


Subject(s)
Attitude to Health , Diabetes Mellitus/classification , International Classification of Diseases/standards , Adolescent , Adult , Aged , Diabetes Mellitus/physiopathology , Diabetes Mellitus/psychology , Female , Focus Groups , Health Status , Humans , Male , Middle Aged , World Health Organization , Young Adult
2.
Eur J Med Res ; 13(8): 383-7, 2008 Aug 18.
Article in English | MEDLINE | ID: mdl-18952521

ABSTRACT

BACKGROUND: Renovascular vasoconstriction in patients with hepatorenal syndrome can be quantified by the renal arterial resistance index (RI). We investigated the value of RI measurement in detection of renal function impairment in patients with different stages of chronic liver disease. METHODS: Subjects were divided into 4 groups containing 21 patients with liver cirrhosis and ascites, 25 patients with liver cirrhosis without ascites, 35 patients with fatty liver disease and 78 control subjects. All patients underwent abdominal ultrasound examination with renal RI measurement and correlation with laboratory results for renal function. RESULTS: RI was significantly higher in ascitic patients compared to non-ascitic patients (0.74 vs. 0.67, p<0.01) and in non-ascitic patients with liver cirrhosis than in control subjects (0.67 vs. 0.62, p<0.01). 48% (19/40) of patients with liver cirrhosis and normal serum creatinine concentration showed elevated RI levels. There were no significant differences in RI levels between patients with fatty liver disease and controls (0.63 vs. 0.62). CONCLUSIONS: Intrarenal RI measurement is a predictor of renal vasoconstriction and serves to detect early renal function impairment in cirrhotic patients. The diagnosis of elevated RI may be taken into account in the clinical management of these patients.


Subject(s)
Kidney Diseases/diagnosis , Kidney Diseases/etiology , Kidney/pathology , Liver Cirrhosis/complications , Liver Cirrhosis/pathology , Adult , Aged , Case-Control Studies , Fatty Liver/diagnosis , Female , Fibrosis , Humans , Kidney Diseases/pathology , Male , Middle Aged , Prognosis , Ultrasonography, Doppler/methods , Vasoconstrictor Agents/pharmacology
3.
Eur J Med Res ; 13(3): 127-30, 2008 Mar 31.
Article in English | MEDLINE | ID: mdl-18499558

ABSTRACT

BACKGROUND: Simultaneous pancreas/kidney transplantation (SPK) should be the procedure of choice for (pre)uremic patients with type 1 diabetes. All standard immunosuppressive protocols for SPK include a calcineurin-inhibitor. Both calcineurin inhibitors, cyclosporine (CyA) and probably tacrolimus (FK506) too, are associated with the occurrence of cholelithiasis due to their metabolic side effects. PATIENTS AND METHODS: We evaluated the prevalence of cholelithiasis in 83 kidney/pancreas transplanted type I-diabetic patients (46 males, 37 females, mean age 42.8 +/- 7.5 years) by conventional B-mode ultrasound 5 years after transplantation. 56 patients received CyA (group 1) and 27 received tacrolimus (group 2) as first-line-immunosuppressive drug. Additional immunosuppression consisted of steroids, azathioprine or mycophenolate mofetil. Additionally, laboratory analyses of cholestasis parameters (gamma-GT and alcalic phosphatasis) were performed. RESULTS: In total, 23 patients (28%) revealed gallstones and 52 patients (62%) revealed a completely normal gallbladder. In eight patients (10%) a cholecystectomy was performed before or during transplantation because of already known gallstones. No concrements in the biliary ducts (choledocholithiasis) could be detected. In group 2 the number of patients with gallstones was slightly lower (22%) compared with group 1 patients (30%), but without statistical significance. - Cholestasis parameters were not increased and HbA1c values were normal in both groups of patients. CONCLUSION: The prevalence of biliary disease in kidney/pancreas transplanted type I-diabetic patients with 28% is increased in comparison to the general population (10-15%). Lithogenicity under tacrolimus seems to be lower as under cyclosporine based immunosuppressive drug treatment. We recommend regular sonographical examinations to detect an acute or chronic cholecystis as early as possible, which may develop occultly in these patients.


Subject(s)
Cholecystolithiasis/complications , Cholecystolithiasis/therapy , Diabetes Mellitus, Type 1/complications , Kidney Transplantation , Pancreas Transplantation , Adult , Cholecystolithiasis/diagnostic imaging , Diabetes Mellitus, Type 1/diagnosis , Female , Humans , Male , Middle Aged , Prevalence , Ultrasonography
4.
Exp Clin Endocrinol Diabetes ; 115(10): 647-53, 2007 Nov.
Article in English | MEDLINE | ID: mdl-18058599

ABSTRACT

INTRODUCTION: Pancreas transplantation in diabetic patients can sustain insulin independence for years. The aim of the study was to measure the incidence of an impaired or diabetic glucose tolerance in patients after successful transplantation and analyse insulin resistance and insulin secretion. METHODS: 174 Type 1 diabetic recipients of simultaneous pancreas/kidney (SPK) transplants were investigated early (three months) and 95 patients late (five years) after transplantation using an oral glucose tolerance test combined with an iv arginine load. RESULTS: Although mean fasting blood glucose and HbA1c levels were within the normal range, only 65% of the patients displayed a normal glucose tolerance (NGT), whereas 25% had an impaired (IGT) and 10% showed a diabetic glucose tolerance (DGT). Fasting blood glucose and HbA1c values were significantly lower in patients with NGT compared to graft recipients with IGT or DGT, either three months or five years after SPK. Indicators of insulin resistance (fasting insulin, HOMA-IR, Matsuda/de Fronzo Index) were elevated in all graft recipients, but no differences were found between groups. In contrast insulin secretion was significantly reduced in patients with IGT and DGT early and late after transplantation. SUMMARY: Insulin resistance is a common feature after pancreas transplantation. However, either three months or five years after SPK abnormal glucose tolerance was mainly due to a reduced glucose- and arginine-induced secretory response of insulin.


Subject(s)
Diabetes Mellitus, Type 1/blood , Fasting/blood , Glucose Tolerance Test , Insulin Resistance , Insulin/blood , Kidney Transplantation , Pancreas Transplantation , Adult , Blood Glucose/analysis , Diabetes Mellitus, Type 1/therapy , Female , Follow-Up Studies , Glycated Hemoglobin/analysis , Humans , Male
5.
Eur J Med Res ; 12(5): 191-5, 2007 May 29.
Article in English | MEDLINE | ID: mdl-17513189

ABSTRACT

BACKGROUND: Our aim was to investigate the influence of age and gender on intrarenal resistance index (RI) measurements in 78 healthy subjects (46 males, 32 females; group 1) and 35 subjects (group 2) with fatty liver disease (28 males and 7 females). SUBJECTS AND METHODS: First, each subject underwent a conventional abdominal ultrasound examination. Then, intrarenal RI values were determined from three distinct interlobar and cortical arteries respectively on both kidneys. The correlation of intrarenal RI with age and gender as a variable was statistically evaluated by linear regression. RESULTS: In group 1, the variables gender, kidney region and comparison of right versus left kidney had no significant effect on intrarenal RI (p>0.05). The variable age, on the other hand, showed a significant positive correlation on all four defined measuring points (p<0.01) with linear correlation coefficients of r = 0.26 (left kidney, central) to r = 0.37 (right kidney, cortical). Therefore normal RI values at ages 25, 45, 65 years could be defined as 0.59, 0.61 and 0.63, respectively. Age dependency can thus be expressed as a function with the formula y = 0.565 + 0.001.x. Patients with fatty liver disease showed age dependency on renal RI (p<0.01) as well. CONCLUSION: In accordance with other studies, the influence of age on intrarenal RI measurement is significant in healthy subjects. Intrarenal RI values from subjects with a fatty liver disease showed age dependency as well. Therefore it is necessary to consider the age of the examined person to interpret RI values correctly.


Subject(s)
Fatty Liver/physiopathology , Kidney/physiology , Renal Circulation/physiology , Vascular Resistance/physiology , Adolescent , Adult , Age Factors , Aged , Female , Functional Laterality/physiology , Humans , Kidney/blood supply , Kidney/diagnostic imaging , Male , Middle Aged , Sex Factors , Ultrasonography, Doppler
6.
Eur J Endocrinol ; 155(1): 73-8, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16793952

ABSTRACT

OBJECT: Treatment with somatostatin analogues (SA) not only inhibits GH secretion but may also impair insulin secretion. In order to evaluate the influence of SA on glucose metabolism, we investigated insulin resistance (IR) and beta-cell function, using the recommended combination of homeostatic model assessment of IR (HOMA-IR) and beta-cell function (HOMA-beta). DESIGN AND METHODS: This is a prospective, cross-sectional study. We measured fasting insulin, blood glucose and IGF-I. Insulin and blood glucose measurements were taken 120 min after an oral glucose tolerance test with 75 g glucose. We studied 51 patients (27 female/24 male, age 54 years (20-75)). Eighteen patients were on Lanreotide Autogel (LA) treatment, 33 had no medical treatment. GH-levels of more than 2.5 ng/ml was reached by 59% of the patients, 74.5% had normal IGF-I levels. RESULTS: We found no significant influence of disease activity on HOMA-IR and HOMA-beta. In the 33 of 51 subjects without any drug treatment, median HOMA-beta was 170.4% (36.0-624.0%). In contrast, in the 18 patients on LA treatment, median HOMA-beta was found to be significantly lower (84.2% (36.5-346.2%); P = 0.001). Despite this, there was no difference in HOMA-IR in both groups (2.4 (0.7-8.4) vs 2.3 (0.7-6.1); P < 0.001) despite similar insulin values. CONCLUSION: In conclusion, we found that LA decreases beta-cell function significantly without affecting IR. Therefore, we think that insulin secretagogues are probably more effective in the treatment of diabetes mellitus in acromegalic patients on LA therapy than insulin sensitizers.


Subject(s)
Acromegaly/drug therapy , Acromegaly/metabolism , Glucose Tolerance Test , Insulin Resistance , Peptides, Cyclic/therapeutic use , Somatostatin/analogs & derivatives , Adult , Aged , Body Mass Index , Cross-Sectional Studies , Female , Gels , Humans , Insulin/blood , Insulin-Secreting Cells/drug effects , Male , Middle Aged , Peptides, Cyclic/administration & dosage , Prospective Studies , Somatostatin/administration & dosage , Somatostatin/therapeutic use
7.
Internist (Berl) ; 47(5): 489-96, 498-501, 2006 May.
Article in German | MEDLINE | ID: mdl-16575611

ABSTRACT

The long-term normalization of glucose metabolism - a prerequisite for the prevention of secondary complications in patients with diabetes mellitus - is only possible by transplantation of a whole pancreas or a reasonable number of islets. An absolute indication for pancreas grafting is given in type 1 diabetic patients with end-stage renal disease. The 1-year survival after simultaneous kidney/pancreas transplantation is, according to the international registry, 94-100% for patients, 89-92% for kidneys and 85-87% for the pancreas. The high success rate with long lasting normalization of glucose metabolism leads to a stabilization and/or amelioration of secondary complications, to an increase in quality of life and, most importantly, to a significant reduction in mortality when compared to diabetic kidney recipients. The indications for islet transplantation are similar to those for pancreatic grafting. Islet grafting is only a minor surgical procedure, but islet isolation is difficult. The 1-year survival for the recipients is 98%, for the islets 82% and for insulin-independency 42%. There is a significant decline of islet function to 10% 5 years after transplantation. Stem cell therapy would provide a definitive treatment solution not only for patients with type 1 diabetes. So far, this therapeutic option is still at an early stage of development.


Subject(s)
Diabetes Mellitus/therapy , Genetic Therapy/methods , Islets of Langerhans Transplantation/methods , Pancreas Transplantation/methods , Stem Cell Transplantation/methods , Combined Modality Therapy , Diabetes Mellitus/mortality , Humans , Immunosuppression Therapy/methods , Kidney Transplantation/methods , Registries , Survival Rate , Treatment Outcome
8.
Internist (Berl) ; 47(2): 141-9, 2006 Feb.
Article in German | MEDLINE | ID: mdl-16374625

ABSTRACT

Overweight and obesity are associated with a high number of complications and co-morbidities. Obesity can affect almost all tissues and organs of the body. Obesity is associated with the components of the metabolic syndrome and is the leading cause of type 2 diabetes. Either obesity itself or co-morbidities of obesity are responsible for the increased cardiovascular risk. The increased overall mortality risk is due to cardiovascular and other complications like the higher prevalence and incidence of malignant tumors. Other complications of obesity like the polycystic ovary syndrome or the obstructive sleep apnea syndrome are relatively unknown but important and frequent. Medical care of people with obesity should focus not only on weight loss but also on complications and co-morbidities.


Subject(s)
Cardiovascular Diseases/complications , Diabetes Mellitus, Type 2/complications , Metabolic Syndrome/complications , Obesity/complications , Obesity/therapy , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/therapy , Cardiovascular Diseases/therapy , Diabetes Mellitus, Type 2/therapy , Humans , Metabolic Syndrome/therapy
9.
Transplant Proc ; 37(6): 2856-8, 2005.
Article in English | MEDLINE | ID: mdl-16182833

ABSTRACT

UNLABELLED: The 3-year data concerning the occurrence of rejection episodes (RE) are reported herein. PATIENTS AND METHODS: Two hundred five simultaneous pancreas-kidney (SPK) transplantations were performed from May 1998 to September 2000, including 103 patients randomly assigned to tacrolimus (Tac) and 102 to cyclosporine microemulsion (CsA-ME). All patients received concomitant rATG induction therapy, mycophenolate mofetil (MMF), and short-term corticosteroids. RESULTS: After a follow-up of 3 years, acute rejection episodes occurred in 41 patients receiving tacrolimus and in 51 patients receiving CsA ME. The majority of first rejection episodes in both groups occurred during the first 6 months (93% and 90%, respectively) and in most cases were treated with corticosteroids (88% and 90%). Actuarial rejection-free graft survival was not significantly different between the two groups (54% and 44% at 3 years posttransplant). In a multivariate analysis, HLA compatibility (P = .003) and graft vessel extension (P = .0005) had a significant influence on rejection-free survival. Rejection influenced pancreatic graft survival (P = .01) and pancreatic graft loss owing to rejection influenced patient survival (P = .02). In the intent-to-treat analysis of early rejection, first moderate-to-severe episodes (1 of 40 versus 12 of 47; P = .004) and refractory episodes (2 of 40 versus 10 of 47; P = .03) were significantly lower with tacrolimus than with CsA ME. Pancreatic graft survival was worse among late rejectors (53%) than nonrejectors (86%; P = .002). In addition, serum creatinine was highest in late rejectors. In conclusion, Tac-based immunosuppressive therapy shows advantages over CsA ME in terms of the severity of acute rejection episodes among patients undergoing SPK transplantation.


Subject(s)
Graft Rejection/etiology , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Pancreas Transplantation/immunology , Acute Disease , Drug Therapy, Combination , Graft Rejection/epidemiology , Graft Rejection/prevention & control , Graft Survival , Humans , Kidney Transplantation/physiology , Pancreas Transplantation/physiology
10.
Exp Clin Endocrinol Diabetes ; 113(3): 139-44, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15789272

ABSTRACT

Lanreotide Autogel (Ipsen) is a long-acting somatostatin analogue (SA) in a new galenic formulation suitable for subcutaneous (s.c.) injection. In our department, 11 patients with therapy-resistant acromegaly were treated with Lanreotide Autogel for 48 months. 10/11 patients had previously undergone transsphenoidal surgery. For a median duration of 1.4 years prior to Lanreotide Autogel, the patients received Lanreotide PR 30 mg every 7, 10, or 14 days. 60, 90, or 120 mg of Lanreotide Autogel was administered by deep s.c. injection every 28 days, with the higher dosage being given to those with the previously shortest injection interval under Lanreotide PR. Dose was adjusted on the basis of Growth Hormone (GH) level after 4, 8, and 12 months with a minimum dose of 60 mg and a maximum dose of 120 mg. The efficacy of Lanreotide Autogel treatment was evaluated by measuring GH concentrations (4 hour profiles) and IGF-I levels. Before switching to Lanreotide Autogel, the multiple of the upper limit of normal (xULN) of IGF-I levels was 1.2 (median) and the median GH level was 1.3 microg/l. 3 out of 11 patients had an IGF-I within the age- and sex-adjusted normal range. After 48 months of treatment with Lanreotide Autogel, six patients had an IGF-I within the normal range. Median GH levels were at 1.3 microg/l and xULN of IGF-I was at 1.0 compared to Lanreotide PR 30 mg treatment (p < 0.001). At the end of the study, 8 patients received 120 mg Lanreotide Autogel, 2 patients 90 mg and 1 patient 60 mg, respectively. There was slight but significant deterioration of glucose metabolism with an increase of HbA1c. In conclusion, the new galenic formulation of Lanreotide improves not only the control of biochemical markers of acromegaly compared to the conventional PR formulation, but is also easier to administer given its deep s.c. method of administration. Glucose metabolism has to be followed carefully in patients on high-dose Lanreotide Autogel.


Subject(s)
Acromegaly/drug therapy , Peptides, Cyclic/therapeutic use , Somatostatin/analogs & derivatives , Somatostatin/therapeutic use , Acromegaly/blood , Aged , Clinical Trials as Topic , Delayed-Action Preparations/therapeutic use , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Gallbladder/diagnostic imaging , Gallstones/chemically induced , Gallstones/diagnostic imaging , Gels , Glycated Hemoglobin/metabolism , Humans , Injections, Subcutaneous , Insulin-Like Growth Factor I/metabolism , Lipids/blood , Male , Middle Aged , Multicenter Studies as Topic , Peptides, Cyclic/administration & dosage , Peptides, Cyclic/adverse effects , Somatostatin/administration & dosage , Somatostatin/adverse effects , Treatment Outcome , Ultrasonography
11.
Transplant Proc ; 35(8): 3081-4, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14697984

ABSTRACT

BACKGROUND: Combined kidney/pancreas transplantation is an established therapy for type 1 diabetic patients with end-stage renal disease. Ultrasound examinations are valuable noninvasive methods for postoperative monitoring of transplant recipients. Kidney grafts are easily to detect, whereas pancreas grafts are surrounded or covered by small bowel loops, which makes the examination much more difficult. PATIENTS AND METHODS: Thirty-three simultaneous pancreas and kidney recipients (SPK) were examined by conventional sonography at 3.4 MHz and THI sonography (pulse inversion, 2.3 MHz) by an investigator experienced in abdominal ultrasound. The images were graded by two "blinded readers" using a scale (1-best image quality, 2-second best, 3-worst) with regard to tissue penetration and detail characterization of the pancreas grafts. The graders were unaware of the sonographic technique, respectively. Statistical evaluation was performed by the Mann-Whitney U test. RESULTS: In 25 cases (78%) pancreas grafts were detected by conventional sonography. The detection rate was higher using THI sonography, namely 29 cases (91%). Grading for tissue penetration revealed a mean value of 2.05 +/- 0.5 for conventional and 1.94 +/- 0.5 for THI sonography (P =.27). Detail characterization of the pancreas grafts was determined to show a mean value of 2.50 +/- 0.5 for conventional sonography and a significantly better mean value of 1.78 +/- 0.6 for THI sonography (P <.0001). CONCLUSION: THI sonography improves the detection and the judgment of tissue characteristics of pancreas grafts. Penetration of ultrasound waves is not relevantly decreased by this new technique.


Subject(s)
Diabetes Mellitus, Type 1/surgery , Pancreas Transplantation/pathology , Pancreas/diagnostic imaging , Ultrasonography/methods , Adult , Body Constitution , Creatinine/blood , Diabetes Mellitus, Type 1/diagnostic imaging , Diabetic Nephropathies/surgery , Female , Glycated Hemoglobin/analysis , Humans , Kidney Failure, Chronic/surgery , Kidney Transplantation , Male , Middle Aged , Observer Variation , Prospective Studies , Treatment Outcome
12.
Am J Physiol Lung Cell Mol Physiol ; 279(5): L977-84, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11053035

ABSTRACT

Extracellular superoxide dismutase (EC-SOD), the only known enzymatic scavenger of extracellular superoxide, may modulate reactions of nitric oxide (NO) in the lungs by preventing reactions between superoxide and NO. The regulation of EC-SOD has not been examined in developing lungs. We hypothesize that EC-SOD plays a pivotal role in the response to increased oxygen tension and NO in the neonatal lung. This study characterizes rabbit EC-SOD and investigates the developmental regulation of EC-SOD activity, protein expression, and localization. Purified rabbit EC-SOD was found to have several unique biochemical attributes distinct from EC-SOD in other species. Rabbit lung EC-SOD contains predominantly uncleaved subunits that do not form disulfide-linked dimers. The lack of intersubunit disulfide bonds may contribute to the decreased heparin affinity and lower EC-SOD content in rabbit lung. EC-SOD activity in rabbit lungs is low before birth and increases soon after gestation. In addition, the enzyme is localized intracellularly in preterm and term rabbit lungs. Secretion of active EC-SOD into the extracellular compartment increases with age. The changes in EC-SOD localization and activity have implications for the neonatal pulmonary response to oxidative stress and the biological activity of NO at birth.


Subject(s)
Extracellular Space/enzymology , Lung/enzymology , Superoxide Dismutase/metabolism , Aging , Amino Acid Sequence , Animals , Animals, Newborn , Aorta/enzymology , Chromatography, Affinity , Disulfides/analysis , Embryonic and Fetal Development , Isoenzymes/chemistry , Isoenzymes/isolation & purification , Isoenzymes/metabolism , Lung/embryology , Lung/growth & development , Molecular Sequence Data , Peptide Fragments/chemistry , Protein Subunits , Rabbits , Superoxide Dismutase/chemistry , Superoxide Dismutase/isolation & purification
13.
Dermatology ; 199(4): 290-5, 1999.
Article in English | MEDLINE | ID: mdl-10640836

ABSTRACT

BACKGROUND: Tripe palms is a descriptive term for a cutaneous paraneoplastic keratoderma. Tripe palms are frequently associated with gastric and pulmonary carcinoma. The pathogenetic mechanism remains unknown. OBJECTIVE: To determine the influence of receptor tyrosine kinases, which are both expressed in pulmonary carcinomas and in human skin, we performed expression studies on epidermal growth factor receptor (EGFR), HER2, HER3 in a skin sample of tripe palms obtained from a patient with non-small-cell lung cancer with lymph node involvement. Two months after diagnosis, the patient had developed palmoplantar 'tripe palms'. Additionally, the expression of SRC, c-myc and p16/ CDKN2 were studied. METHOD: Conventional reverse-transcription polymerase chain reaction was performed on a tissue sample of tripe palms. RESULTS: Weak expression of HER2 and of p16/CDKN2 was found. EGFR, HER3, c-myc and SRC were not expressed. CONCLUSION: Receptor tyrosine kinases of subclass I, the tyrosine kinase SRC and the oncogene c-myc play no major role in the pathogenesis of this case of tripe palms.


Subject(s)
Carcinoma, Non-Small-Cell Lung/complications , Cyclin-Dependent Kinase Inhibitor p16/genetics , Keratosis/pathology , Lung Neoplasms/complications , Paraneoplastic Syndromes/pathology , Receptor Protein-Tyrosine Kinases/genetics , Aged , Carcinoma, Non-Small-Cell Lung/genetics , Gene Expression Regulation , Humans , Keratosis/complications , Keratosis/genetics , Lung Neoplasms/genetics , Paraneoplastic Syndromes/complications , Paraneoplastic Syndromes/genetics , Reverse Transcriptase Polymerase Chain Reaction
14.
AIDS ; 12(15): F167-73, 1998 Oct 22.
Article in English | MEDLINE | ID: mdl-9814858

ABSTRACT

BACKGROUND: The use of protease inhibitors in the treatment of HIV-1 infection is associated with the new onset of diabetes mellitus, hyperlipidaemia and lipodystrophy. It is unclear whether these findings are coincidental or whether they reflect a causative effect of protease inhibitors. OBJECTIVE: To evaluate the effect of treatment with protease inhibitors on insulin sensitivity, oral glucose tolerance and serum lipids in HIV-infected patients in order to determine whether treatment with protease inhibitors can cause peripheral insulin resistance. DESIGN: Cross-sectional controlled study in HIV-infected patients treated with protease inhibitors to assess insulin sensitivity, oral glucose tolerance and changes in serum lipids. METHODS: Sixty-seven patients treated with protease inhibitors, 13 therapy-naive patients and 18 HIV-negative control subjects were tested for insulin sensitivity (intravenous insulin tolerance test). In a subgroup of 24 treated patients, oral glucose tolerance was determined. Serum lipids prior to and under treatment with protease inhibitors were compared. RESULTS: Patients on protease inhibitors had a significantly decreased insulin sensitivity when compared with therapy-naive patients (median, 75 and 156 micromol/l/min, respectively; P < 0.001). All treated patients with impaired (n=4) or diabetic (n=9) oral glucose tolerance, and four out of 11 patients with normal glucose tolerance showed peripheral insulin resistance; all therapy-naive patients had normal insulin sensitivity. Treatment with protease inhibitors led to a significant increase in total triglycerides and cholesterol in the 67 treated patients (median increase, 113 and 37 mg/ml, respectively). CONCLUSION: Treatment with protease inhibitors is associated with peripheral insulin resistance, leading to impaired or diabetic oral glucose tolerance in some of the patients, and with hyperlipidaemia. Overall, there is a large variation in the severity and clinical presentation of protease inhibitor-associated metabolic side-effects.


Subject(s)
Anti-HIV Agents/adverse effects , Glucose Tolerance Test , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , Insulin Resistance , Adult , Cholesterol/blood , Female , HIV Infections/blood , HIV Infections/physiopathology , HIV-1 , Humans , Male , Middle Aged , Triglycerides/blood
16.
Horm Metab Res ; 10(4): 263-8, 1978 Jul.
Article in English | MEDLINE | ID: mdl-680626

ABSTRACT

The influence of exercise on forearm muscle metabolism was examined in 9 healthy subjects, in 16 diabetics and in 4 obese subjects during complete starvation. During exercise glucose uptake rose 7-8 fold in the controls. However, no increase of glucose uptake was observed in the other groups studied. Moreover, a glucose production from the working muscle took place in about 40 percent of both the diabetic patients and the starved obese subjects. The nonutilization of glucose during physical work in the diabetic like states was accompanied by a significantly diminished lactate output. The arterial concentration of FFA, glycerol beta-HOB and Acac was markedly elevated in the starved obese patients. The FFA-uptake at rest and during exercise, however, was not different from results of controls. Whereas an effux of beta-HOB has been observed during exercise, Acac uptake was increased in these patients. It is suggested that in maturity onset and starvation diabetes glycolysis is inhibited.


Subject(s)
Diabetes Mellitus/metabolism , Muscles/metabolism , Obesity/metabolism , Physical Exertion , Adult , Blood Glucose , Fatty Acids, Nonesterified/blood , Glycolysis , Humans , Insulin/blood , Lactates/metabolism , Middle Aged , Pyruvates/metabolism , Starvation/metabolism
18.
Res Exp Med (Berl) ; 168(1): 23-33, 1976 Jul 22.
Article in German | MEDLINE | ID: mdl-981812

ABSTRACT

The influence of insulin on muscle metabolism at rest and during electrically stimulated exercise was examined in the perfused rat hind limb. Basal glucose uptake of muscle tissue was enhanced threefold both by muscle contraction an by addition of physiological amounts of insulin. A further increase in glucose uptake was seen, when muscle was exercised in the presence of insulin. Lactate production rose 7 - 8fold by contractions. Insulin had no additional effect on lactate production during exercise. The work-induced lactate output exceeded glucose uptake, corresponding to a significantly reduced glycogen content after exercise. Basal lipolysis was not stimulated by muscle contractions. At rest the addition of both corticosterone and thyroxine did not increase the basal lipolysis. Yet, glycerol release rose twofold by the addition of serum to the perfusion medium. It is assumed that in the perfused rat hind limb glycogenolysis will promptly be stimulated by muscle contractions, whereas lipolysis can not be enhanced by exercise alone.


Subject(s)
Glucose/metabolism , Lipid Metabolism , Muscles/metabolism , Physical Exertion , Animals , Electric Stimulation , Fatty Acids, Nonesterified/metabolism , Glycerol/metabolism , Glycogen/metabolism , Hindlimb , In Vitro Techniques , Insulin/pharmacology , Lactates/biosynthesis , Male , Perfusion , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...